Amicus Therapeutics Inc (FOLD)

06:23 AM

Leerink Partnrs Issues Optimistic Outlook for FOLD Earnings - MarketBeat

06:23 AM

Jan 21, 2025

Q2 Earnings Forecast for FOLD Issued By Leerink Partnrs - MarketBeat

Jan 21, 2025

Jan 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Jan 21, 2025

Jan 20, 2025

Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey

Jan 20, 2025

Jan 17, 2025

Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential - Yahoo Finance

Jan 17, 2025

Jan 17, 2025

Jefferies Initiates Coverage of Amicus Therapeutics (FOLD) with Buy Recommendation - MSN

Jan 17, 2025

Jan 17, 2025

Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World

Jan 17, 2025

Jan 15, 2025

Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Jan 15, 2025

Jan 15, 2025

Enzyme Replacement Therapy Market Deep Research Report with - openPR

Jan 15, 2025

Jan 15, 2025

When (FOLD) Moves Investors should Listen - Stock Traders Daily

Jan 15, 2025

Jan 15, 2025

Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88 - MarketBeat

Jan 15, 2025

Jan 15, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Jan 15, 2025

Jan 14, 2025

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN

Jan 14, 2025

Jan 13, 2025

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpStill a Buy? - MarketBeat

Jan 13, 2025

Jan 13, 2025

Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC - MarketBeat

Jan 13, 2025

Jan 13, 2025

Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN

Jan 13, 2025

Jan 13, 2025

A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts - Benzinga

Jan 13, 2025

Jan 13, 2025

Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week - Yahoo Finance

Jan 13, 2025

Jan 13, 2025

Fabry Disease Treatment Market Top Companies StudySanofi SA, - openPR

Jan 13, 2025

Jan 12, 2025

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewswire

Jan 12, 2025

Jan 12, 2025

Amicus Therapeutics Reports Stellar 32% Revenue Growth to $528.5M, Eyes $1B Sales Target - StockTitan

Jan 12, 2025

Jan 12, 2025

Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? - Insider Monkey

Jan 12, 2025

Jan 11, 2025

12 Best Medical Stocks To Buy Under $20 - Insider Monkey

Jan 11, 2025

Jan 11, 2025

Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Canada

Jan 11, 2025

Jan 10, 2025

Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat

Jan 10, 2025

Jan 10, 2025

Amicus Therapeutics stock hits 52-week low at $9.01 - Investing.com

Jan 10, 2025

Jan 07, 2025

Principal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jan 07, 2025

Jan 07, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - MarketBeat

Jan 07, 2025

Jan 04, 2025

How the (FOLD) price action is used to our Advantage - Stock Traders Daily

Jan 04, 2025

Jan 02, 2025

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 02, 2025

Jan 02, 2025

Amicus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 02, 2025

Jan 02, 2025

JPMorgan Chase & Co. Sells 1,984,751 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jan 02, 2025

Jan 02, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co. - Defense World

Jan 02, 2025

Jan 01, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update - MarketBeat

Jan 01, 2025

Dec 30, 2024

Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues - Simply Wall St

Dec 30, 2024

Dec 27, 2024

Amicus Therapeutics: Cheap Heading Into 2025 (NASDAQ:FOLD) - Seeking Alpha

Dec 27, 2024

Dec 24, 2024

Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Dec 24, 2024

Dec 22, 2024

Geode Capital Management LLC Acquires 80,926 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Dec 22, 2024

Dec 21, 2024

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 21, 2024

Dec 20, 2024

Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR

Dec 20, 2024

Dec 19, 2024

FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com

Dec 19, 2024

Dec 18, 2024

Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat

Dec 18, 2024

Dec 17, 2024

Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Dec 17, 2024

Dec 16, 2024

Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat

Dec 16, 2024

Dec 16, 2024

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat

Dec 16, 2024

Dec 15, 2024

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World

Dec 15, 2024